Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

NCT04597359 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT04597359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04597359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 5, 2021
Completion date
December 31, 2027
Enrollment
360 (estimated)
Sites
353

Conditions

As the registry lists them; a condition with its own page is linked.

prostate carcinoma